Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 6,018 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $38.48, for a total transaction of $231,572.64. Following the completion of the transaction, the chief financial officer owned 38,000 shares of the company’s stock, valued at approximately $1,462,240. This trade represents a 13.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Thursday, September 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $50.35, for a total transaction of $303,006.30.
• On Monday, August 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $58.58, for a total value of $352,534.44.

Enliven Therapeutics Stock Performance

NASDAQ:ELVN opened at $41.82 on Thursday. Enliven Therapeutics, Inc. has a 52 week low of $14.78 and a 52 week high of $62.32. The stock’s 50-day moving average price is $50.93 and its 200-day moving average price is $48.00.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.

Trending Headlines about Enliven Therapeutics

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $73 price target, substantially above the recent trading level. The firm forecasts a 2026 loss of $1.74 per share, slightly better than the $1.81 consensus estimate, providing a positive valuation signal if the company meets expectations.
• Positive Sentiment: HC Wainwright expects quarterly losses of $0.41 per share in Q3 2026 and $0.46 in Q4 2026, followed by losses of $0.48, $0.50, $0.52 and $0.55 per share in the first four quarters of 2027. While still unprofitable, the estimates give investors a forward outlook and support the analyst’s bullish target.
• Neutral Sentiment: The firm projects a full-year 2027 loss of $2.06 per share, underscoring that Enliven remains a development-stage biotechnology company dependent on future clinical and commercial progress rather than current earnings.
• Negative Sentiment: CFO Benjamin Hohl sold 6,018 shares for approximately $231,573, reducing his direct ownership by 13.67%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which makes it less concerning than an unexpected discretionary sale, but it may still weigh on sentiment. SEC insider transaction filing

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ELVN. JonesTrading upped their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Mizuho lifted their price target on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. William Blair began coverage on shares of Enliven Therapeutics in a report on Tuesday, August 18th. They issued an “outperform” rating for the company. Finally, Guggenheim restated a “buy” rating on shares of Enliven Therapeutics in a research report on Thursday, October 8th. Ten analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Enliven Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $75.44.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Enliven Therapeutics during the second quarter valued at approximately $221,255,000. First Light Asset Management LLC lifted its position in shares of Enliven Therapeutics by 574.1% in the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock valued at $69,058,000 after acquiring an additional 1,158,883 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Enliven Therapeutics by 276.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock valued at $52,898,000 after acquiring an additional 847,399 shares in the last quarter. Siren L.L.C. acquired a new stake in shares of Enliven Therapeutics in the first quarter worth approximately $29,252,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Enliven Therapeutics in the second quarter worth approximately $30,617,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.